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Current eradication strategies of tuberculosis (TB) in goats mainly rely on the single
intradermal tuberculin test (SIT) and single intradermal cervical comparative tuberculin
tests (SICCTs). TB vaccination has been proposed as a cost-effective option in
high-prevalence herds or countries where economic compensation for the slaughter of
positive animals is not affordable. However, TB vaccination compromises the efficiency
of tuberculin-based diagnostic tests. In this study, the performance of a new diagnostic
platform, based on the P22 antigenic complex, was assessed for skin test (ST),
interferon-gamma release assay (IGRA), and serology under different TB scenarios. The
sensitivity (Se) of diagnostic tests was assessed in TB-infected goats from the same
farm (herd A, N = 77). The specificity (Sp) was assessed in two TB-negative farms
(both vaccinated against paratuberculosis): one TB unvaccinated (herd B, N = 77) and
another vaccinated with bacille Calmette-Guérin (BCG) (herd C, N = 68). The single
(s) P22-IGRA showed the highest Se among IGRA tests (91%), and the comparative
(c) P22-ST showed the highest Sp (100% in herd B and 98% in herd C). Combined
interpretation of techniques enabled the best diagnostic performances. Combining the
SICCT + sP22-IGRA improved Se (97%) compared to SICCT + tuberculin-based IGRA
(95%), with a reduction of Sp (95 and 100%, respectively). Besides, combination of
P22-ELISA with cP22-ST or SICCT elicited a similar performance in the non-vaccination
context (Se: 94 and 95%; Sp: 95 and 95%, respectively), but Sp was significantly higher
for the combination with cP22-ST compared to SICCT in the TB vaccination context
(95 and 79%, respectively). The combination of serological tests based on P22 and
MPB83 showed higher complementarity and improved 13 percentage points the Se of
P22-ELISA alone. These findings suggest that either cell-mediated or antibody-based
diagnostic techniques, using the P22 antigen complex, can contribute to improve the
immunodiagnostics of TB in goats under different TB control strategies.
Keywords: tuberculosis, diagnosis, goats, bacille Calmette-Guérin (BCG), skin test, interferon-gamma release
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INTRODUCTION
Tuberculosis (TB) in goats is a chronic infectious disease, mainly
caused by Mycobacterium bovis and Mycobacterium caprae,
members of the Mycobacterium tuberculosis complex (MTBC).
This disease entails important economic costs for livestock
industries (1) and could be a source of TB for cattle (2), other
domestic animals (3, 4), wildlife (5), and humans (6).
Spain has the second-highest goat census of the EU, with
2.7 million goat heads (data extracted from FAOSTAT on
17/02/2020). Besides, the high TB burden in goats could explain
a number of new bovine TB breakdowns, hampering the goal
of TB eradication in cattle (7). Therefore, some regions with a
high concentration of caprine herds carry out TB eradication
campaigns in caprine flocks (8); however, goat herds are still
not subjected to a national eradication program, except for those
epidemiologically linked with cattle (9).
The cornerstone of an efficient caprine TB eradication
program is the diagnosis. The Spanish bovine TB eradication
program effectiveness is highly dependent on the routine
tuberculin skin testing (10). Current bovine TB testing is based
on the single intradermal tuberculin test (SIT) and single
intradermal cervical comparative tuberculin tests (SICCTs), and
the interferon-gamma release assay (IGRA). However, in goats
under certain epidemiological contexts, those diagnostic tests
have some drawbacks in terms of sensitivity (Se) and specificity
(Sp) (8, 11).
Another concern for TB diagnostics is the vaccination against
Mycobacterium avium subsp. paratuberculosis (MAP), which
has been largely implemented in small ruminants, to prevent
the development of clinical disease (12). Nevertheless, even
though MAP vaccines are authorized (e.g., Gudair R© vaccine), it
has been demonstrated that paratuberculosis (PTB) vaccination
interferes with STs and IGRA used for TB diagnosis (13, 14). In
addition, the efficacy ofM. bovis bacille Calmette-Guérin (BCG)
vaccine has also been assessed in goats during the last decade
in different vaccination trials (15–19). Even though these trials
showed that BCG conferred certain protection to experimentally
and naturally infected goats, it was evidenced that vaccination
interfered with current TB diagnostic tests (16, 20).
To overcome diagnostic interferences due to BCG
vaccination, defined antigens to differentiate infected from
vaccinated animals (DIVA) have been developed (14, 21);
nevertheless, those antigens have shown lower Se compared to
tests based on standard tuberculins (22). Recently, a new multi-
protein complex called P22, obtained from purified protein
derivative of M. bovis (PPD-B) by affinity chromatography, has
been developed (23), yielding high Se and variable Sp, depending
on the animal species and epidemiological contexts (24). To
date, this antigen has been tested to detect humoral response
against MTBC in different species (25–30); however, there is a
lack of information regarding its performance for cell-mediated
immunity (CMI)-based diagnostics.
The aim of this study was to evaluate the performance of
different cell-mediated and humoral immunodiagnostic tests,
based on the P22 antigenic complex, for the diagnosis of TB in
goats under different epidemiological and control scenarios.
MATERIALS AND METHODS
Herds and Experimental Design
A total of 222 goats from three herds were included in the
study (Table 1): 77 infected goats (infection was confirmed
postmortem by gross lesions, histopathology or mycobacterial
culture, or both) from a TB-positive herd of murciana-granadina
goats (herd A); 77 goats belonging to an officially TB-free herd
of alpine goats (herd B) that were vaccinated against PTB with
Gudair (CZ Vaccines, Porriño, Spain), around 2 years before
sampling; and 68 goats from another TB-free herd (herd C) of
Blanca de Rasquera autochthonous breed, that were vaccinated
against PTB (Gudair R©) and against TB with M. bovis BCG
Danish 1,331 strain (ATCC, Ref. 35733) as described previously
(15). In herd C, 50% of goats were vaccinated with BCG and
Gudair R© 9–10 months before sampling, and the remaining 50%
were vaccinated more than 1 year before. STs, IGRAs, and
immunoglobulin G (IgG) enzyme-linked immunosorbent assays
(ELISAs) were carried out in the 77 infected goats, as well as in
138, 142, and 142 noninfected goats, respectively (Table 1).
Two TB control scenarios were hypothesized in order to study
the performance of each diagnostic test: the conventional (TB
unvaccinated) scenario, using data from herds A and B, and the
BCG-vaccinated (TB-VAC) scenario, using data from herds A
and C. Se was calculated using data from herd A, and Sp was
calculated using data from herds B and C depending on TB
control scenario (Table 2).
Antigens
M. tuberculosis var. bovis (PPD-B) and M. avium (PPD-A)
tuberculins (2,500 IU/ml) were obtained from CZ Vaccines
TABLE 1 | Herd and treatment distribution of tested animals.
No. of animals tested
Herd TB status BCG1 Gudair®2 ST IGRA ELISA
A Positive No No 77 77 77
B Free No Yes 77 74 74
C Free Yes Yes 61 68 68
1BCG, bacilli Calmette-Guérin Mycobacterium bovis vaccine. 2Gudair vaccine, vaccine
against paratuberculosis (Mycobacteium avium subspecies paratuberculosis).
TB, tuberculosis; ST, skin test; IGRA, interferon-gamma release assay.
TABLE 2 | TB control scenarios distribution of tested animals.
No. of animals tested
Control scenario Herds BCG1 Gudair®2 ST IGRA ELISA
Conventionala A+B No Yes 154 151 151
TB-VACb A+C Yes Yes 138 145 145
aConventional scenario: composed by TB unvaccinated goats. bTB-VAC Scenario: TB
negative animals from herd C were vaccinated with BCG and TB-positive animals
from herd A were not vaccinated. 1BCG, bacilli Calmette-Guérin Mycobacterium
bovis vaccine. 2Gudair vaccine, vaccine against paratuberculosis (Mycobacteium avium
subspecies paratuberculosis).
TB, tuberculosis; ST, skin test; IGRA, interferon-gamma release assay.
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and used at concentrations recommended by the Spanish
Ministry (9). The protein complex P22 was produced by
immunopurification of PPD-B (CZ Vaccines) as described
previously (23) and prepared at a concentration of 500µg/ml
(unpublished data). The DIVA reagent based on a cocktail of
recombinant ESAT-6 and CFP-10 proteins (500µg/ml) (31) and
the recombinant MPB83 (MPT83) protein (500µg/ml) (32) were
purchased from Lionex (Braunschweig, Germany).
Skin Tests
SIT was performed by intradermal inoculation of 0.1ml of PPD-
B in the left-hand side of the neck by using a Dermojet R© syringe
(Akra Dermojet, Pau, France). In the same way, SICCT was
performed by intradermal inoculation of 0.1ml of PPD-B and
PPD-A, both in the left-hand side of the neck, at the proximal
and distal parts of the neck, respectively. Besides, 0.1ml of P22
(at 500µg/ml) was inoculated in the right-hand side of the
neck. The increase in skinfold thickness (SFT) was measured
just before the inoculation and after 72 h. Severe interpretations
of SIT and SICCT were performed, as previously described in
the manual of the Spanish bovine TB eradication program (9).
Briefly, positive criterion for SIT: SFT PPD-B > 2mm (severe);
and for SICCT: positive to SIT and SFT PPD-B - SFT PPD-
A > 1mm (severe) or presence of clinical signs in the PPD-B
inoculation site. P22 single and comparative STs (sP22-ST and
cP22-ST) were interpreted using the same criteria as SIT and
SICCT, respectively, i.e., considering SFT P22 and SFT P22 - SFT
PPD-A measures, respectively.
Whole-Blood Interferon-Gamma Release
Assays
Blood samples were collected from the jugular vein prior to
ST performance using heparinized tubes and were processed as
described previously (16). Shortly, blood samples were stimulated
with PPD-B, PPD-A, and P22 at a final concentration of
20µg/ml, and with DIVA reagent (ESAT-6/CFP-10) at 20µg/ml,
while PBS was added as an unstimulated control. Samples were
incubated at 37 ± 1◦C with 0.5% CO2 overnight. Finally, plasma
supernatant was collected and analyzed by ELISA (BOVIGAM R©,
Thermo Fisher Scientific, Waltham, MA, USA) and read at
450 nm using a spectrophotometer (Biotek PowerWave XS). The
interpretation of tuberculin-based IGRA (STAND-IGRA) results
was performed according to the cutoff point recommended by
the manufacturer, i.e., the criterion for positivity: PPD-B OD –
PBS OD ≥ 0.05 and PPD-B OD > PPD-A OD. Similarly, cP22-
IGRA was considered positive when P22 OD – PBS OD ≥ 0.05
and P22OD> PPD-AOD, whereas sP22-IGRA andDIVA-IGRA
were considered positive when P22 OD – PBS OD ≥ 0.05 and
DIVA OD – PBS OD ≥ 0.05, respectively.
Antibody Detection Tests
Plasma samples were analyzed for antibody detection by using
two in-house indirect ELISA, one for detecting MPB83 antigen,
performed and interpreted as described previously (33), and
another one for detecting P22, performed as described previously
(24, 25). P22-ELISA was interpreted as follows: ELISA percentage
(E%) = [mean sample OD/(2 × mean negative control OD)] ×
100. A sample E%<100% was classified as negative, and a sample
E% ≥100% was classified as positive.
Post-mortem Examination
Seventy-seven goats from the positive herd (herd A) were
euthanized after ST reading by intravenous injection of a sodium
pentobarbital overdose. A complete necropsy procedure was
conducted for TB lesion examination. Lesions were collected and
immediately fixed in 10% buffered formalin for histopathological
confirmation by hematoxylin/eosin staining. Mediastinal and
tracheobronchial lymph nodes (LNs) were removed and stored
at−20◦C for bacterial culture.
Bacteriology
Whole pulmonary LNs of each animal were thawed, pooled,
homogenized, and decontaminated as previously described (34)
and plated on Middlebrook 7H11 medium (BD diagnostics,
Sparks, MD, USA). Then, cultured plates were incubated at
37◦C for 28 days. Finally, plates were read, and colonies were
confirmed as MTBC by multiplex PCR (35).
Data Analysis
The Sp was calculated in TB-free farms (herds B and C) using the
formula Sp = True negatives/(True negatives + False positives).
The Se was calculated in the TB-infected farm by the formula
Se = True positive/(True positive + False negative). Clooper-
Pearson 95% confidence intervals were calculated for Sp and Se.
Differences in diagnostic results, between tests, were evaluated
by the McNemar test. Moreover, agreement between tests was
calculated by Cohen’s Kappa coefficient (k) and interpreted as
follows: <0.00 poor, 0.00–0.20 slight, 0.21–0.4 fair, 0.41–0.60
moderate, 0.61–0.80 substantial, and 0.81–1.00 almost perfect.
The diagnostic performance of each test was calculated using the
diagnostic odds ratio (DOR) (36). All statistical tests and 95%
confidence intervals were calculated using the Epitools calculator
(Sargento, ESG, 2018, Epitools Epidemiological Calculators,
Ausvet, Pty., Ltd., Australia; available in www.epitools.ausvet.
com.au).
RESULTS
The results of Se of herd A and Sp of herds B and C are
summarized in Table 3. The TB-positive status of all animals
from herd A was confirmed by positive mycobacterial culture
and/or positive lesions in histopathological analysis.
Skin Tests
The Se of the cP22-ST was the lowest among tests, but the Sp in
herd Bwas the highest, being identical to the Sp of the SICCT, and
a 6 percentage point (p.p.) and 8 p.p. more specific than the SIT
and the sP22-ST, respectively. Regarding the herd C, the cP22-ST
and the sP22-ST displayed similar Sp, being significantly more
specific than the SIT (31 p.p. of increase, p < 0.001, and 30 p.p.
of increase, p= 0.005, for cP22-ST and sP22-ST, respectively) and
the SICCT (18 p.p. of increase, p= 0.0026, and 17 p.p. of increase,
p= 0.0094, for cP22-ST and sP22-ST, respectively).
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TABLE 3 | Sensitivity (Se) and specificity (Sp) of diagnostic tests.
Diagnostic
test
TB positive
(farm A)
Unvaccinated
(farm B)
BCG vaccinated
(farm C)
N9 Se
(95% CI)10
N Sp
(95% CI11
N Sp
(95% CI)11
sP22-ST1 77 87% (77–94) 77 92% (84–97) 61 97% (89–100)
cP22-ST2 77 74% (63–83) 77 100%
(95–100)
61 98% (91–100)
SIT3 77 94% (85–98) 77 94% (85–98) 61 67% (54–79)
SICCT4 77 91% (82–96) 77 100%
(95–100)
61 80% (68–89)
sP22-IGRA5 77 91% (82–96) 74 95% (87–99) 68 84% (73–92)
cP22-IGRA6 77 86% (76–93) 74 96% (89–99) 68 85% (75–93)
STAND-
IGRA7
77 77% (66–86) 74 100%
(95–100)
68 96% (88–99)
DIVA-IGRA8 77 71% (60–81) 74 100%
(95–100)
68 100%
(95–100)
P22-ELISA 77 74% (63–83) 74 93% (85–98) 68 96% (88–99)
MPB83-
ELISA
77 75% (64–84) 74 92% (83–97) 68 94% (86–98)
1sP22-ST, single P22 skin test; 2cP22-ST, comparative P22 skin test; 3SIT, single
intradermal tuberculin test; 4SICCT, single intradermal cervical comparative tuberculin
test; 5sP22-IGRA, single P22 IGRA test; 6cP22-IGRA, comparative P22 IGRA test;
7STAND-IGRA, standard tuberculin IGRA test; 8DIVA-IGRA, differentiating Infected from
Vaccinated animals (ESAT-6/CFP-10 peptide cocktail) IGRA test. 9Number of animals
tested. 10Clopper–Pearson 95% confidence interval for Se. 11Clopper–Pearson 95%
confidence interval for Sp.
TB, tuberculosis; BCG, bacille Calmette-Guérin; IGRA, interferon-gamma release assay.
Interferon-Gamma Release Assays
The sP22-IGRA showed the highest Se among tests, being a 5,
14, and 20 p.p. more sensitive than the cP22-IGRA, the STAND-
IGRA, and the DIVA-IGRA, respectively. Indeed, the sP22-IGRA
detected 12 positive goats more than the STAND-IGRA, without
significant agreement between tests (k = 0.4, p = 0.098) and
diagnostic results significantly different (Supplementary Data, p
= 0.005). The sP22-IGRA and the cP22-IGRA showed similar
specificities in both herds B and C, being a 4–5 p.p. less
specific than the STAND-IGRA and the DIVA-IGRA. In herd
C, both cP22-IGRA and sP22-IGRA were a 10–9 p.p. and a
16–15 p.p. less specific than the STAND-IGRA and the DIVA-
IGRA, respectively.
Serological Tests
In terms of Sp and Se, diagnostic results of P22-ELISA were
similar to diagnostic results of MPB83-ELISA. In herd A, the
MPB83-ELISA detected 10 TB positive animals more than
the P22-ELISA, and the P22-ELISA detected nine TB positive
animals more than the MPB83-ELISA, and the agreement
between tests was considered fair although statistically significant
(k = 0.35, p = 0.001). In herd B, diagnostic results of Sp showed
a moderate but significant agreement between ELISA tests (k =
0.51, p < 0.001), but in herd C, no agreement was observed (k =
−0.05, p= 0.33).
TABLE 4 | Sensitivity (Se) and specificity (Sp) combined results of P22-based
diagnostic tests.
Diagnostic
tests
TB positive
(farm A)
Unvaccinated
(farm B)
BCG vaccinated
(farm C)
N8 Se
(95% CI)9
N Sp
(95% CI)10
N Sp
(95% CI)10
SIT1 +
sP22-IGRA2
77 97% (91–100) 73 89% (80–95) 61 59% (46–71)
SIT +
cP22-IGRA3
77 97% (91–100) 73 90% (81–96) 61 61% (47–73)
SIT +
P22-ELISA
77 96% (89–99) 73 89% (80–95) 61 66% (52–77)
SICCT4 +
sP22-IGRA
77 97% (91–100) 73 95% (87–98) 61 67% (54–79)
SICCT +
cP22-IGRA
77 97% (91–100) 73 96% (88–99) 61 67% (54–79)
SICCT +
P22-ELISA
77 95% (87–99) 73 95% (87–98) 61 79% (66–88)
sP22-ST5 +
sP22-IGRA
77 95% (87–99) 73 88% (78–94) 61 82% (70–91)
sP22-ST +
P22-ELISA
77 94% (85–98) 73 88% (78–94) 61 93% (84–98)
cP22-ST6 +
sP22-IGRA
77 95% (87–99) 73 95% (87–98) 61 84% (72–92)
cP22-ST +
P22-ELISA
77 94% (85–98) 73 95% (87–98) 61 95% (86–99)
sP22-IGRA +
STAND-IGRA7
77 92% (84–97) 74 95% (87–99) 68 84% (73–92)
P22-ELISA +
sP22-IGRA
77 95% (87–99) 74 89% (80–95) 68 79% (68–88)
P22 ELISA +
cP22-IGRA
77 95% (87–99) 74 91% (81–96) 68 81% (70–89)
P22-ELISA +
MPB83-ELISA
77 87% (77–94) 74 92% (83–97) 68 90% (80–96)
P22-ELISA +
STAND-IGRA
77 90% (81–95) 74 93% (85–98) 68 91% (82–97)
SIT +
STAND-IGRA
77 95% (87–99) 73 93% (85–98) 61 67% (54–79)
SICCT +
STAND-IGRA
77 95% (87–99) 73 100%
(95–100)
61 80% (68–89)
1SIT, single intradermal tuberculin test; 2sP22-IGRA, single P22 IGRA test; 3cP22-IGRA,
comparative P22 IGRA test; 4SICCT, single intradermal cervical comparative intradermal
tuberculin test; 5sP22-ST, single P22 skin test; 6cP22-ST, comparative P22 skin test;
7STAND-IGRA, standard tuberculin IGRA test. 8Number of animals tested; 9Clopper–
Pearson 95% confidence interval for Se. 10Clopper–Pearson 95% confidence interval
for Sp.
TB, tuberculosis; BCG, bacille Calmette-Guérin; IGRA, interferon-gamma release assay.
Complementarity of Diagnostic Tests
Combined interpretation of P22-based tests was evaluated.
Results of Sp and Se of complementarity of diagnostic tests are
shown in Table 4. In general, complementarity between tests
yielded an overall rise of Se with a variable reduction in the Sp.
The combination of cP22-ST+ P22 ELISA improved the Se in
20 p.p. and displayed a similar Sp in both herds B and C, being
the combined interpretation with the best results in all situations.
The combination of SICCT + P22 ELISA showed similar results
of Se and Sp in herd B. In herd C, the latter combination detected
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10 false-positives more than the cP22-ST+ P22-ELISA, reducing
its Sp in 16 p.p., and with diagnostic results significantly different
between tests (p = 0.004). The combination of cP22-ST + cP22-
IGRA improved the Se and Sp in herd B at a similar level than the
combined interpretations above described, but in herd C, the Sp
was reduced in 11 p.p. respect to the cP22-ST+ P22-ELISA test.
The combination of current diagnostic tests, e.g., SIT and
SICCT, with other diagnostic tests increased the Se but not the Sp,
except for the SICCT + STAND-IGRA. The latter combination
improved the Se in 4 and 18 p.p. compared to the SICCT and
the STAND-IGRA alone, respectively, and maintained the Sp
in herd B but not in herd C (reduction of 16 p.p. compared
to the STAND-IGRA alone). In herd A, the combined results
of MPB83-ELISA + P22-ELISA improved the Se in 12 and 13
p.p. with respect to the MPB83-ELISA and the P22-ELISA alone,
respectively, and maintained the Sp in herd B, and in herd
C showed a mild reduction of Sp (4 and 6 p.p. of reduction
with respect to the MPB83-ELISA and the P22-ELISA alone,
respectively). Other combinations of tests did not improve the Se
and the Sp, as did the aforementioned combined interpretations.
Performance of Diagnostic Tests
The results of DOR to assess the diagnostic performance for each
test are represented in Figure 1. In general, a reduced DOR in
TB-VAC scenario was observed compared to the conventional
one (0.47, 95% CI: 0.28–0.654, of mean reduction in log DOR).
In the conventional context, SICCT + STAND-IGRA (3.38, 95%
CI: 2.35–4.41), SICCT alone (3.16, 95% CI: 2.36–3.97), SICCT
+ cP22-IGRA (2.94, 95% CI: 1.12–4.76), and SICCT + sP22-
IGRA (2.81, 95% CI: 1.08–4.54) showed the best performances
(Figure 1A). In TB-VAC context, the best performances were
observed in DIVA IGRA (2.53, 95% CI: 1.98–3.8), cP22-ST +
P22 ELISA (2.44, 95% CI: 0.97–3.92), and sP22-ST + P22 ELISA
(2.31, 95% CI: 0.95–3.67) (Figure 1B).
DISCUSSION
Efficient and accurate diagnosis is of paramount importance for
the success of eradication programs based on test and slaughter
strategy. Here, the performance of new P22 antigenic complex-
based cell-mediated and humoral tests for the diagnosis of TB
in goats was assessed under different epidemiological and TB
control scenarios.
Recently, the P22 antigenic complex has been evaluated for
the detection of IgG in ELISA tests in different species: cattle
goat, sheep, pigs, and wild boar (24–27), red deer (28), badgers
(29), and alpacas and llamas (30). In the present study, the
performance of the P22 antigenic complex for diagnostic tests
based on CMI, namely, STs and IGRA, was evaluated for the
first time in goats. Indeed, the use of P22 for IGRA tests has
only been reported in red deer experimentally infected with M.
bovis (37).
The combined interpretation of tests leads to a substantial
improvement of Se at the expense of a variable loss of Sp.
As expected, in the conventional context, the SICCT alone or
combined with the STAND-IGRA (8, 11, 38) showed the best
performances by DOR analysis. The performances of tuberculin-
based tests were followed by the combinations of SICCT with
the P22-IGRAs, which increased Se at the cost of a certain loss
in Sp. Moreover, the combination of cP22-ST + P22-ELISA
clearly increased the Se with the benefit of a minimal decrease
of Sp, showing similar results than the combination of SICCT
+ P22-ELISA. These findings are in concordance with previous
studies of P22-ELISA and tuberculin-based skin testing. In cattle,
the combination of SIT + P22-ELISA showed an improvement
of Se of 30 and 6 p.p. compared to the SIT and the P22-
ELISA alone, respectively (25). In another study conducted in
goats (39), the same combination improved the Se of the SIT
and the P22-ELISA in 19 and 9.5 p.p., respectively. Also, in
the same study in goats, the combination of SICCT + P22-
ELISA improved the Se of the SICCT in a 24 p.p. These results
confirmed the benefits of the strategic use of serological and
CMI-based diagnostic tests in parallel to maximize the Se in
infected settings.
In the TB-VAC context, the combination of P22-ELISA with
the two P22-based STs showed similar performances than the
DIVA-IGRA. However, the latter showed considerably lower
Se than the combinations of P22-ELISA with P22-based STs
(reduction in 23–24 p.p.). Previous studies reported the excellent
Sp (16) and the lack of Se (40) of DIVA-IGRA, although the
DOR analysis tended to overestimate the Sp in this study. The Se
of vaccine-associated diagnostic tests is an essential requirement
for the development of an integral vaccination strategy (41),
and the combination of cP22-ST + P22-ELISA showed an
efficient and innovative diagnostic approach in the TB-VAC
context, showing the highest combined Se and Sp values (94 and
95%, respectively).
Concerning the use of the ST in solitary, the P22-based STs
showed lower Se compared to both the SIT and the SICCT tests,
although previous studies in dairy goat flocks, with larger samples
and different epidemiological situations, have shown lower Se
for SIT (65%, 95% CI: 63.3–68.2) (8) and SICCT (44.5%, 95%
CI: 35–55) (42). However, the Se of the cP22-ST (74%, 95%
CI: 63–83) was similar to Se observed in two previous studies
using DIVA STs (based on the peptide cocktails ESAT-6, CFP-
10, and Rv3616c) developed for the diagnosis of TB in cattle:
76%, 95% CI: 59–93 (43) and 75%, 95% CI: 47.7–97.7 (44). In
the latter, the addition of the Rv3020c peptide improved the
Se to reach 87.5% (95% CI: 61.7–98.5), being similar to the
Se of sP22-ST (87%, 95% CI: 74–94) obtained in the present
study. On the other hand, in BCG-vaccinated animals, the Sp
of SIT and SICCT decreased dramatically (27 and 20 p.p. of
reduction, respectively), whereas the Sp of sP22-ST and cP22-
ST remained high (97 and 98%, respectively). These findings
again highlight the suitability of P22-based STs as TB vaccine-
associated diagnostic candidates, although improvements to
increase the Se should be necessary.
Moreover, herd PTB status and MAP vaccination may also
affect the interpretation of the results. MAP infection was not
reported in farms B and C, and no recent clinical history of
PTB was observed by the veterinarians. Despite this, vaccination
against MAP is a common practice in small ruminants in
Spain (12), and diagnostic interferences due to MAP vaccination
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FIGURE 1 | Diagnostic test performance measured by diagnostic odds ratio (DOR). (A) Conventional (unvaccinated scenario). (B) Tuberculosis (TB)-VAC scenario,
animals were vaccinated with Mycobacterium bovis bacille Calmette-Guérin (BCG). sP22-ST, single P22 skin test; cP22-ST, comparative P22 intradermal skin test;
SIT, single intradermal tuberculin test; SICCT, single intradermal cervical comparative tuberculin test; sP22-IGRA, single P22 interferon-gamma release assay (IGRA)
test; cP22-IGRA, comparative P22 IGRA test; STAND-IGRA, standard tuberculin IGRA test; DIVA-IGRA, differentiating infected from vaccinated animals
(ESAT-6/CFP-10 peptide cocktail) IGRA test.
on TB diagnosis cannot be ruled out in these two MAP-
vaccinated herds. In this sense, strong reactions to PPD-A were
observed at skin testing (Supplementary Data), but the results
of comparative tests (cP22-ST and SICCT) showed higher Sp
compared to their respective single STs (i.e., sP22-ST and SIT).
These findings indicate that some degree of cross-reactivity due
to MAP vaccination was still maintained. Similarly, interferences
of MAP vaccination on TB diagnosis, mainly in CMI-based
diagnostic tests, were previously observed in MAP-vaccinated
goats (14, 45).
Surprisingly, the P22-based IGRAs, particularly the sP22-
IGRA, showed higher Se compared to STAND-IGRA and even
higher compared to DIVA-IGRA. However, the Se of sP22-IGRA
was similar to that previously observed by the STAND-IGRA
(92%, 95% CI: 84–96) in other studies conducted in goats (26).
The results of Se of the cP22-IGRA in the present study were
also similar to those previously observed in experimentally M.
bovis-infected red deer (37). However, a slight loss of Sp in
the P22-IGRAs was detected compared to STAND-IGRA. Even
so, the Sp was within ranges (95–100%) described for STAND-
IGRA in previous studies (11, 38, 45). This mild reduction
in Sp could be explained by the high concentration of P22
used for stimulation of whole blood (20µg/ml) and by the
fact that P22 complex contains 21 proteins also present in
M. avium (23), which can cause cross-reactivity with MAP
vaccination and/or infection. Indeed, the interference of MAP
vaccination on STAND-IGRA has been previously observed in
adult MAP-vaccinated goats (13, 14, 45). The Sp of P22-IGRAs
considerably decreased in BCG-vaccinated herds compared to
that previously described for the STAND-IGRA (16). Overall,
the results of sP22-IGRA suggest that this test could be a
potentially valuable tool for TB eradication in endemic areas,
although further studies to determine the optimal concentration
of P22 are required to improve its Sp with a minimal
loss of Se.
Serological diagnostics is a cost-effective alternative for
TB diagnostics. However, the Se of antibody-based diagnostic
tests was generally lower compared to tests based on CMI
(46, 47). In the present study, the Se of P22-ELISA was
slightly lower than that in previous studies in goats and
cattle (25, 39). This loss of Sp might be explained by the
fact that animals from herd A were not vaccinated against
MAP nor subjected to frequent intradermal testing, factors that
could enhance humoral responses against MTBC antigens (48).
Interestingly, the Se was significantly enhanced when using P22
and MPB83 ELISAs in parallel. Thus, even though MPB83 is
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a major component of the P22 complex, specific IgGs of some
infected animals were only detectable using the MPB83 purified
recombinant protein alone, while others were only detected
using the P22 complex, which contains additional serodominant
epitopes (23).
Finally, Sp of the P22-ELISA reached considerably higher
Sp in MAP-vaccinated (and BCG-unvaccinated, i.e., herd B)
goats (93%) compared to that previously found in Spanish
(78%) and Norwegian MAP-vaccinated goats (58%) (24). In the
latter study, besides MAP vaccination, MAP coinfection and/or
contact with environmental mycobacteria was not discarded as
a source of diagnostic interference. Interestingly, in the present
study, the Sp was also high in BCG- and MAP-vaccinated goats
(96%), suggesting that BCG vaccination does not induce antibody
responses that cause interference on the diagnosis by the P22-
ELISA. The absence of antibody responses was consistent with
the fact that the BCGDanish strain used for vaccination expresses
low levels of MPB83 and MPB70 (49), which are the most
abundant proteins of the P22 antigenic complex (23). Moreover,
tuberculin skin testing after 42 days of MAP or BCG vaccination
caused a boosting effect on humoral responses against tuberculin
antigens, resulting in false-positive cattle for an MPB83-based
ELISA (50). Here, minimal or no boosting effects of MAP/BCG
vaccination due to skin testing were observed on the P22-ELISA.
Indeed, goats from herd B were sampled around 2 years after
vaccination against MAP, and ST was performed once or twice
after MAP vaccination. Also, 34/68 goats from herd C were
vaccinated with BCG and Gudair R© at 9–10 months before the
sampling, whereas the rest of the animals were vaccinated more
than 1 year before, and no ST was performed since. Based on
the results herein, the P22-ELISA seemed to be a useful ancillary
diagnostic tool, either in BCG or MAP vaccination context,
although it should be confirmed in further studies with larger
sized herds.
In conclusion, this study reinforces the applicability of the
P22 antigen complex as a complementary instrument for TB
diagnostics in goats under different control scenarios. The
P22 serological diagnostic is a cost-effective alternative, and
combined interpretation with STs, either with PPD-B or P22,
showed promising results. Moreover, the use of P22 antigenic
complex in CMI-based diagnostic tests showed encouraging
results, being suitable for further research on the improvement
of TB diagnostics.
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